One of them focuses on the use of sera from patients with breast cancer, but in this approach, a variety of elements may alter the Akt’s expression and activity, such as chemotherapy, hormonal therapy, and target therapy present in the serum of these patients [58–61]. Here, AKT1 is linked to breast cancer.